According to Cryptopolitan, the former CEO of the Singaporean crypto lending platform Hodlnaut, Zhu Juntao, has been charged with six counts of fraudulent misrepresentation for allegedly misleading users about the exposure to TerraUSD. Hodlnaut invested $317 million from user accounts into Terra's Anchor Protocol without disclosure, resulting in a loss of $189.7 million after the UST collapse. When the platform shut down in August 2022, it owed users approximately $281 million, with assets of only $88 million, creating a shortfall of about $193 million.
Prosecutors allege that Zhu Juntao instructed employees to make false promises in official Telegram groups and emails during and after the UST collapse, including claims that the company had not invested in LUNA or UST and had not suffered losses. Zhu Juntao pleaded not guilty in court, and a pre-trial conference is scheduled for June 2026. If convicted, each charge carries a maximum sentence of 20 years in prison.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.



Key Takeaways: Tether’s USDT supply reaches an all-time high of $188 billion, maintaining its dominance in the stablecoin…

Imagine having a reliable digital dollar that moves seamlessly across blockchain networks, much like how cash flows effortlessly…

Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.










Key Takeaways: Tether’s USDT supply reaches an all-time high of $188 billion, maintaining its dominance in the stablecoin…
Imagine having a reliable digital dollar that moves seamlessly across blockchain networks, much like how cash flows effortlessly…
Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.